Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Carcinogenicity

Currently viewing:

Administrative data

Description of key information

In accordance with column 2 of REACH Annex X No. 8.9.1, the study does not need to be conducted as 
- in all in vitro and in vivo genotoxitity studies performed, no evidence was found that the substance induced any mutagenic or genotoxic response and
- there was no evidence from the repeated dose studies that the substance is able to induce hyperplasia or pre-neoplastic lesions.

Key value for chemical safety assessment

Carcinogenicity: via oral route

Endpoint conclusion
Endpoint conclusion:
no study available

Carcinogenicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
no study available

Carcinogenicity: via dermal route

Endpoint conclusion
Endpoint conclusion:
no study available

Justification for classification or non-classification

There is no evidence for a muutagenic or carcinogenic potential of n-Butyl Acetate. Therefore a carcinogenicity classification is not justified.

Additional information

In accordance with column 2 of REACH Annex X No. 8.9.1, the study does not need to be conducted as

- in all in vitro and in vivo genotoxitity studies performed, no evidence was found that the substance induced any mutagenic or genotoxic response and

- there was no evidence from the repeated dose studies that the substance is able to induce hyperplasia or pre-neoplastic lesions.


Justification for selection of carcinogenicity via oral route endpoint:
No carcinogenicity study is required, since the substance is not mutagenic and no hyperplasia or pre-neoplastic lesions were observed in any available studies.

Justification for selection of carcinogenicity via inhalation route endpoint:
No carcinogenicity study is required, since the substance is not mutagenic and no hyperplasia or pre-neoplastic lesions were observed in any available studies.

Justification for selection of carcinogenicity via dermal route endpoint:
No carcinogenicity study is required, since the substance is not mutagenic and no hyperplasia or pre-neoplastic lesions were observed in any available studies.